Diabetic Macular Edema / Diabetic Retinopathy | Disease Landscape & Forecast | G7 | 2024
Diabetic macular edema (DME) is a complication of diabetic retinopathy (DR) derived from chronically high blood sugar levels, resulting in vision loss and blindness if left untreated. DME treatments include the anti-VEGF inhibitors Eylea, Lucentis, Beovu, Eylea HD, and off-label Avastin. Other approved agents for DME include the corticosteroid implants Ozurdex and Iluvien and the anti-VEGF / Ang-2 bispecific antibody Vabysmo. In the United States, Lucentis 0.3 mg, Eylea, and Eylea HD are approved for all forms of DR without DME, whereas Lucentis 0.5 mg is approved for proliferative diabetic retinopathy (PDR) in Europe. Competition in the DR / DME market will increase with the launch of biosimilars of Lucentis and Eylea and with the potential approval of key emerging therapies such as Roche’s ranibizumab port delivery system (Susvimo), promising longer dosing intervals. Non-intravitreal (IVT) agents such as Oculis’s OCS-01, a topical eye drop formulation, will likely result in a paradigm shift and may revolutionize the management of DME patients in the future.
Questions answered
- How large is the treatable DR / DME population, and how will diagnosis and drug-treatment rates change over time?
- Do KOLs perceive any differences between current IVT therapies? How is the use of these drugs expected to change over the next 10 years?
- How will the DR / DME treatment algorithm change as innovative products launch?
- How will market dynamics be impacted by the launch of biosimilars of Lucentis and Eylea?
Product description
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research.
Key features
Disease Landscape & Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.
Disease Landscape & Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.
